全文获取类型
收费全文 | 11989篇 |
免费 | 1018篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 193篇 |
儿科学 | 266篇 |
妇产科学 | 196篇 |
基础医学 | 1630篇 |
口腔科学 | 164篇 |
临床医学 | 1283篇 |
内科学 | 2583篇 |
皮肤病学 | 162篇 |
神经病学 | 1112篇 |
特种医学 | 413篇 |
外科学 | 1870篇 |
综合类 | 171篇 |
一般理论 | 27篇 |
预防医学 | 1037篇 |
眼科学 | 175篇 |
药学 | 887篇 |
中国医学 | 7篇 |
肿瘤学 | 866篇 |
出版年
2023年 | 110篇 |
2022年 | 79篇 |
2021年 | 369篇 |
2020年 | 236篇 |
2019年 | 399篇 |
2018年 | 527篇 |
2017年 | 369篇 |
2016年 | 360篇 |
2015年 | 380篇 |
2014年 | 537篇 |
2013年 | 581篇 |
2012年 | 1017篇 |
2011年 | 1001篇 |
2010年 | 588篇 |
2009年 | 508篇 |
2008年 | 831篇 |
2007年 | 823篇 |
2006年 | 765篇 |
2005年 | 760篇 |
2004年 | 716篇 |
2003年 | 531篇 |
2002年 | 528篇 |
2001年 | 105篇 |
2000年 | 88篇 |
1999年 | 83篇 |
1998年 | 84篇 |
1997年 | 60篇 |
1996年 | 51篇 |
1995年 | 50篇 |
1994年 | 52篇 |
1993年 | 40篇 |
1992年 | 34篇 |
1991年 | 33篇 |
1990年 | 37篇 |
1989年 | 37篇 |
1988年 | 31篇 |
1987年 | 24篇 |
1986年 | 26篇 |
1985年 | 26篇 |
1984年 | 18篇 |
1983年 | 17篇 |
1982年 | 12篇 |
1981年 | 16篇 |
1980年 | 9篇 |
1976年 | 10篇 |
1972年 | 5篇 |
1970年 | 8篇 |
1969年 | 6篇 |
1967年 | 5篇 |
1966年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders 总被引:6,自引:0,他引:6
Lee WM Dienstag JL Lindsay KL Lok AS Bonkovsky HL Shiffman ML Everson GT Di Bisceglie AM Morgan TR Ghany MG Morishima C Wright EC Everhart JE;HALT-C Trial Group 《Controlled clinical trials》2004,25(5):472-492
The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial was designed to determine whether maintenance interferon therapy could slow disease progression in patients who had failed to eradicate hepatitis C virus (HCV) during prior interferon treatment (nonresponders). Ten clinical sites, a virological testing center, and a data coordinating center (DCC) were selected to collaborate in the design and implementation of the final protocol. Eligible patients had been treated previously with interferon for at least 12 weeks, with or without another antiviral, ribavirin, but still had persistent viremia. Because patients had received a variety of prior treatments, and as a perceived benefit of enrollment, we incorporated a Lead-in period of treatment with long-acting pegylated interferon alfa-2a plus ribavirin into the study design, a combination believed to be more effective but not approved by the Food and Drug Administration at the Trial's inception. If patients failed to achieve clearance of virus from the blood after 20 weeks of this Lead-in therapy, they were entered into the main trial at week 24 and randomized to receive either a lower dose of pegylated interferon weekly alone or no further therapy for an additional 3 1/2 years. The original protocol was amended later in three respects to improve enrollment and to adapt to Food and Drug Administration approval of the Lead-in therapy, including allowing patients to proceed directly to the randomized part of the study if treatment resembling the Lead-in had been completed. The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity. 相似文献
82.
83.
84.
85.
Aubé Mélanie Chua Michael DeLong Jessica McCammon Kurt Tonkin Jeremy Gilbert David Virasoro Ramón 《International urology and nephrology》2020,52(4):687-692
International Urology and Nephrology - To determine predictors for surgical complications and assess patient satisfaction after surgical treatment of Adult-Acquired Buried Penis (AABP). A... 相似文献
86.
The traditional transurethral resection of the prostate (TURP) is considered as gold-standard surgical treatment to relieve symptoms resulting from bladder outlet obstruction by prostate enlargement. However, with the advances of novel laser technologies and more experienced surgeon conquering the steep learning curve, anatomical endoscopic enucleation of prostate (AEEP) has become a more popular alternative surgical technique. Although AEEP has compatible functional outcome, less blood loss, shorter catheterisation duration and hospital stay, the risk of post-operative urinary incontinence (UI) is often an issue of concern. In this review, we focus on discussion about risk factors related to increased incidence of UI, some surgical tips to avoid damaging external urinary sphincter and treatment strategies to facilitate recovery of urinary continence after surgery. 相似文献
87.
Interventional Efforts to Reduce Psychological Distress After Orthopedic Trauma: A Systematic Review
Kirven James C. Everhart Joshua S. DiBartola Alex C. Jones Jeremy Flanigan David C. Harrison Ryan 《HSS journal》2020,16(3):250-260
HSS Journal ® - Unanticipated severe injury to part of the musculoskeletal system, referred to as orthopedic trauma, can be debilitating. It can also be accompanied by equally debilitating... 相似文献
88.
Recombinant human ADAMTS13 treatment and anti‐NET strategies enhance skin allograft survival in mice
Siu Ling Wong Jeremy Goverman Caleb Staudinger Denisa D. Wagner 《American journal of transplantation》2020,20(4):1162-1169
Enhancing skin allograft longevity lessens the need for new allografts before optimal intervention is available. Reduced activity of ADAMTS13 (an enzyme that cleaves the pro‐thrombotic and proinflammatory von Willebrand factor) and presence of neutrophil extracellular traps (NETs) have been implicated in liver and lung allograft failures. The effect of ADAMTS13 treatment and the impact of NETs on skin allografts, however, remain unexplored. Here, we adopted a murine model of complete mismatch full‐thickness skin transplant by grafting dorsal skin from BALB/c mice to C57BL/6J background mice. Recombinant human ADAMTS13 (rhADAMTS13) treatment of graft recipients increased allograft survival. Western blot and immunofluorescence microscopy revealed the presence of NETs in allografts of vehicle, but surprisingly, not in rhADAMTS13‐treated mice, 3 days after surgery. Recapitulating the observations in mice, NETs were also observed in all the examined allografts from burn patients. Intriguingly, knocking out peptidylarginine deiminase 4 (PAD4, a key enzyme for NET formation) or DNase 1 treatment (which cleaves NETs) also prolonged allograft survival. In summary, rhADAMTS13 lessens inflammation in allografts by reducing NET burden, resulting in enhanced allograft survival. RhADAMTS13 and anti‐NET treatments could be new therapeutic strategies to promote skin allograft longevity and, hence, the survival of patients with severe burns. 相似文献
89.
Dwyer Anthony Huckleby Jeremy Kabbani Majid Delano Angela De Sutter Michelle Crawford David 《Journal of robotic surgery》2020,14(3):387-392
Journal of Robotic Surgery - Inadequacies exist in the ergonomics of upper body positioning of robotic surgeons; these deficits in biomechanical efficacy predispose surgeons to musculoskeletal... 相似文献
90.
Phebe de Heus Jolanta Kolodziejek Jeremy V. Camp Katharina Dimmel Zoltn Bag Zdenek Hublek Ren van den Hoven Jessika‐M. V. Cavalleri Norbert Nowotny 《Transboundary and Emerging Diseases》2020,67(3):1189-1197
We report details of the first seven equine cases of confirmed West Nile neuroinvasive disease in Austria. The cases presented during summer and autumn of 2016 (n = 2), 2017 (n = 3) and 2018 (n = 2). All horses showed gait abnormalities and 6 of 7 horses exhibited fasciculations and/or tremors, and we provide video recordings of these. Three horses also showed cranial nerve involvement. Following rapid improvement, three horses were discharged. Four horses were euthanized due to the severity of clinical signs and subjected to neuropathological examination. West Nile virus (WNV) lineage 2 nucleic acid was detected in 5 of 7 horses, and WNV‐specific neutralizing antibodies in all 7 horses. In addition, serologic evidence of WNV infection was found in two out of fourteen in‐contact horses. Horses may be considered a sentinel species for human WNV infections, integrating human and veterinary medicine and thus contributing to the one health concept. 相似文献